Retatrutide vs Tirzepatide: What the Glucagon Arm Changes
By Peptura Research Team/17 May 2026/8 min read
Two From the Same Stable
Tirzepatide and Retatrutide are both synthetic peptide research compounds from Eli Lilly, and both act on the incretin signalling axis. What separates them is the number of receptors they hit. Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Retatrutide keeps both and adds agonism at the glucagon receptor (GCGR), giving a triple-action incretin profile. That single mechanistic addition accounts for most of the divergence seen between the two in research.
Tirzepatide: The Dual Mechanism
Tirzepatide acts at GIPR and GLP-1R together, two receptors tied to glucose-dependent insulin secretion, glucagon modulation, and central appetite signalling. GLP-1 receptor activation slows gastric emptying and drives satiety pathways in the hypothalamic arcuate nucleus. GIP receptor activation lifts insulin secretion in response to elevated glucose and shapes energy storage in adipose tissue. Together they produce greater metabolic effects in research models than single GLP-1 agonism, as the SURPASS clinical trial programme published from 2021 onward set out.
Retatrutide: Adding the Third Arm
Retatrutide retains GIPR and GLP-1R agonism and layers glucagon receptor (GCGR) activation on top. In the liver, glucagon receptor signalling promotes hepatic glucose output, raises fatty acid oxidation, and lifts resting energy expenditure. Set against a dual GLP-1/GIP background, that third axis pushes the energy balance further toward catabolic metabolism. Phase 2 data in the New England Journal of Medicine in 2023 reported roughly 24% body-weight reduction at 48 weeks at the highest dose tested, beyond any dual or single agonist in the published incretin literature.
The Point of Divergence
The meaningful split is the glucagon arm. In healthy hepatic tissue, glucagon receptor activation ramps up gluconeogenesis, which on its own would raise blood glucose. Within Retatrutide, though, the simultaneous GLP-1 and GIP signalling drives insulin secretion that offsets it, yielding a net gain in energy expenditure without glucose dysregulation. The open research question is whether this triple mechanism produces a distinct metabolic phenotype that single or dual agonists simply cannot reach.
Kinetics
Both peptides are engineered for once-weekly administration in research protocols, using fatty acid moieties that promote albumin binding and stretch the half-life. Tirzepatide runs a half-life of about 5 days; Retatrutide reports around 6 days in published pharmacokinetic data. That longer window supports stable plasma concentrations under weekly dosing in research models.
Research Status
Tirzepatide is approved for clinical use in several jurisdictions for type 2 diabetes and obesity research applications. Retatrutide is still in Phase 3 clinical trials as of 2024. Neither is approved for human use in the UK by the MHRA. Both are restricted to in-vitro laboratory research and authorised preclinical studies only. Peptura supplies Retatrutide 10mg, Retatrutide 20mg, and Retatrutide 30mg for research use only, not for human or veterinary application.
Laboratory Handling
Both compounds come as lyophilised powder. Store at -20°C until reconstitution. Reconstitute with bacteriostatic water by running the diluent slowly down the side of the vial and swirling gently. Never shake a reconstituted peptide solution. Keep reconstituted solutions at 2-8°C and use within four weeks, avoiding repeated freeze-thaw cycles that erode integrity.
Sourcing in the UK
Peptura supplies research-grade Retatrutide 10mg, Retatrutide 20mg, and Retatrutide 30mg at 99.6% HPLC purity (batch PEP-742) with full third-party Certificate of Analysis published on every product page. Same-day UK dispatch on orders placed before 2pm GMT. Royal Mail Tracked 24 delivery, free over £45. For in-vitro laboratory research use only.
Related Products
Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. Peptura products are not for human consumption and are sold strictly for laboratory research use only.